stockrowAlto Neuroscience, Inc. (ANRO) vs Rigel Pharmaceuticals, Inc. (RIGL)
- Alto Neuroscience, Inc. ANRO 25.16 +15.04%
- Rigel Pharmaceuticals, Inc. RIGL 39.59 −13.39%
Alto Neuroscience, Inc. and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Alto Neuroscience, Inc. and Rigel Pharmaceuticals, Inc. are of similar size ($858.2M and $853.9M). Alto Neuroscience, Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.4×. Rigel Pharmaceuticals, Inc. has the higher net margin (106.6% vs 0.00%) and the higher return on invested capital (13.7% vs 0.00%). Across the 13 metrics below, Rigel Pharmaceuticals, Inc. leads on 12 and Alto Neuroscience, Inc. on 1.
Valuation
Profitability
| Metric | ANRO | RIGL | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 89.64% | 68.51% |
| Operating margin | 0.00% | 26.28% | 0.00% |
| Net margin | 0.00% | 106.59% | 0.00% |
| Free cash flow margin | 0.00% | 31.20% | 0.00% |
| Return on equity | (49.17%) | 109.18% | (51.96%) |
| Return on assets | (40.90%) | 80.16% | (46.06%) |
| Return on invested capital | 0.00% | 13.69% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack